pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$KPTIKaryopharm Therapeutics Inc.

$KPTI
Newton, MA, USupdated 21d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Marketed: 1Unknown: 1
1Marketed1Unknown
Marketed
selinexor
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Exportin-1
drug
XPOVIO
1 INDICATIONS AND USAGE XPOVIO is a nuclear export inhibi…
Exportin-1

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruitingn=501
  • phase3Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinomarecruitingn=276
  • phase3Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]completedn=263
  • phase3Study of Selinexor in Combination With Ruxolitinib in Myelofibrosisactive not recruitingn=353
  • —Karyopharm Expanded Access Program for Selinexoravailable
  • phase2A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopeniarecruitingn=58
  • phase2A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.recruitingn=127
  • phase2Selinexor and Backbone Treatments of Multiple Myeloma Patientsrecruitingn=300
more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 21, 26SELLRangwala Reshma· EVP & Chief Medical Officer449 sh @ $8.94−$4K↗
  • Mar 2, 26SELLPaulson Richard A.· President and CEO12,361 sh @ $9.41−$116K↗
  • Mar 2, 26SELLPoulton Stuart· EVP, Chief Development Officer5,101 sh @ $9.41−$48K↗
  • Mar 2, 26SELLRangwala Reshma· EVP & Chief Medical Officer5,066 sh @ $9.41−$48K↗
  • Mar 2, 26SELLCheng Sohanya Roshan· EVP & Chief Commercial Officer4,604 sh @ $9.41−$43K↗
  • Mar 2, 26SELLMano Michael· EVP, CLO&Secretary3,526 sh @ $9.41−$33K↗
  • Mar 2, 26SELLAbate Kristin· Chief Accounting Officer559 sh @ $9.41−$5K↗
🐶 Hiring Signal
No open roles indexed yet — view Karyopharm Therapeutics Inc. jobs →

News

  • Karyopharm has a month left to salvage its cancer expansion plans
    A commercial-stage cancer drugmaker with a market cap about one-third the size of its projected 2026 revenues is on the brink of defaulting. Karyopharm Therapeutics said Thursday that it has until ...
    endpoints · 7d ago
identifiers
ticker
$KPTI
SEC CIK
0001503802
country
US
source
sec_tickers
top tags
DLBCL1Oncology1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 10m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?